Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ATM | Q13315 | 6/20 | 0.44 |
| ▸ | TRPA1 | O75762 | 4/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | HPGD | P15428 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.37 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.37 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.37 |
| ▸ | DPP4 | P27487 | 1/20 | 0.36 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.36 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.35 |
| ▸ | PIK3R1 | P27986 | 1/20 | 0.35 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.35 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.35 |
| ▸ | NPC1 | O15118 | 1/20 | 0.35 |
| ▸ | RAB9A | P51151 | 1/20 | 0.35 |
| ▸ | GABRA2 | P47869 | 1/20 | 0.35 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12629375 | 0.91 | TRPA1 (0.44) | TRPA1KDM4EHPGDSMN1; SMN2PIK3CD | |
| SCHEMBL2034986 | 0.80 | TRPA1 (0.41) | ATMTRPA1KDM4EHPGDSMN1; SMN2 | |
| Trifluoroacetic Acid SCHEMBL2017034 | 0.80 | PIK3CD (0.48) | PIK3CDPIK3R1PIK3CBPIK3CG | |
| SCHEMBL12357166 | 0.79 | MDM2 (0.45) | TRPA1KDM4EHPGDSMN1; SMN2CYP1A2 | |
| Hydrochloric Acid SCHEMBL2040122 | 0.78 | MDM2 (0.44) | TRPA1KDM4EHPGDSMN1; SMN2CYP1A2 | |
| SCHEMBL2043010 | 0.76 | TRPA1 (0.38) | ATMTRPA1KDM4EHPGDSMN1; SMN2 | |
| SCHEMBL12357171 | 0.76 | SLC2A1 (0.41) | TRPA1KDM4EHPGDSMN1; SMN2CYP1A2 | |
| SCHEMBL2018019 | 0.74 | PIK3CD (0.45) | KDM4ESMN1; SMN2CYP1A2CYP2C9CYP2C19 | |
| SCHEMBL2017634 | 0.73 | CYP1A2 (0.55) | TRPA1KDM4EHPGDCYP1A2CYP2C9 | |
| SCHEMBL2504442 | 0.72 | PIK3CD (0.55) | PIK3CDPIK3R1PIK3CBPIK3CG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9403847-B2 | Substituted heteroaryl fused derivatives as P13K inhibitors | INCYTE HOLDINGS CORPORATION (US) | 2016-08-02 | — | — | US | disclosed |
| US-20140275127-A1 | SUBSTITUTED HETEROARYL FUSED DERIVATIVES AS PI3K INHIBITORS | INCYTE CORPORATION (US) | 2014-09-18 | — | — | US | disclosed |
| US-8759359-B2 | Substituted heteroaryl fused derivatives as PI3K inhibitors | INCYTE CORPORATION (US) | 2014-06-24 | — | — | US | disclosed |
| US-20110190319-A1 | SUBSTITUTED HETEROARYL FUSED DERIVATIVES AS PI3K INHIBITORS | INCYTE CORPORATION | 2011-08-04 | — | — | US | disclosed |
| WO-2011075643-A1 | SUBSTITUTED HETEROARYL FUSED DERIVATIVES AS PI3K INHIBITORS | INCYTE CORPORATION (US) | 2011-06-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110190319-A1 | SUBSTITUTED HETEROARYL FUSED DERIVATIVES AS PI3K INHIBITORS | PIK3CA, PIK3CD, PIK3R5 | ATM 497/4885TRPA1 4725/4885KDM4E 1889/4885 |
| US-20140275127-A1 | SUBSTITUTED HETEROARYL FUSED DERIVATIVES AS PI3K INHIBITORS | PIK3CA, PIK3CD, PIK3R5 | ATM 497/4885TRPA1 4725/4885KDM4E 1889/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.